| New oral anticoagulants: a practical guide for clinicians. | |
| | |
MedLine Citation:
|
PMID: 19888552 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The search for an oral anticoagulant with acceptable efficacy and safety in the treatment and prevention of venous and arterial thromboembolism, but with practical advantages over warfarin, has been a focus of drug development for many years. Three oral agents, dabigatran, rivaroxaban, and apixaban, are nearing approval in the US. Their use in practice will be guided by the clinical trials available, as well as their pharmacokinetic and pharmacodynamic properties. Practitioners need to be fully aware of these characteristics in order to use these agents appropriately in clinical practice. This review compares the results of the phase 3 trials investigating these agents in the prevention of venous thromboembolism in patients undergoing orthopedic surgery, examines the reporting of bleeding complications in the trials, and highlights various practical considerations regarding their use in clinical practice. |
| | |
Authors:
|
Ann K Wittkowsky |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: 29 ISSN: 1573-742X ISO Abbreviation: J. Thromb. Thrombolysis Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-29 Completed Date: 2010-04-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 182-91 Citation Subset: IM |
Affiliation:
|
University of Washington School of Pharmacy, Seattle, WA, USA. akwitt@u.washington.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / administration & dosage*, adverse effects, pharmacokinetics Benzimidazoles / administration & dosage Clinical Trials, Phase III as Topic Drugs, Investigational / administration & dosage*, adverse effects Evidence-Based Medicine Humans Morpholines / administration & dosage Orthopedic Procedures / adverse effects* Practice Guidelines as Topic Pyrazoles / administration & dosage Pyridines / administration & dosage Pyridones / administration & dosage Thiophenes / administration & dosage Venous Thromboembolism / etiology, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Benzimidazoles; 0/Drugs, Investigational; 0/Morpholines; 0/Pyrazoles; 0/Pyridines; 0/Pyridones; 0/Thiophenes; 0/apixaban; 0/rivaroxaban; 211915-06-9/dabigatran etexilate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hepatocyte growth factor-mediated attraction of mesenchymal stem cells for apoptotic neuronal and ca...
Next Document: Physician alerts to prevent venous thromboembolism.